Importance of Endogenous Fibrinolysis in Platelet Thrombus Formation.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
clopidogrel 1 angiologydiseasesdrugs
thrombosis 18 angiologydiseases
vascular disease 6 angiologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
clopidogrel 23258 for arterial thrombosis relies on antiplatelet agents, such as aspirin, and P2Y12 inhibitors, such as clopidogrel or ticagrelor, to help alleviate the pro-thrombotic environment. However, use of such medications to
Select Disease Character Offset Disease Term Instance
thrombosis 506 6LY, UKPublication date (epub): 8/2017Publication date (collection): 9/2017AbstractThe processes of thrombosis and coagulation are finely regulated by endogenous fibrinolysis maintaining healthy equilibrium. When
thrombosis 762 platelet activation and/or coagulation, or if endogenous fibrinolysis becomes less efficient, pathological thrombosis can occur. Arterial thrombosis remains a major cause of morbidity and mortality in the world despite
thrombosis 793 coagulation, or if endogenous fibrinolysis becomes less efficient, pathological thrombosis can occur. Arterial thrombosis remains a major cause of morbidity and mortality in the world despite advances in medical therapies.
thrombosis 970 despite advances in medical therapies. The role endogenous fibrinolysis in the pathogenesis of arterial thrombosis has gained increasing attention in recent years as it presents novel ways to prevent and treat existing
thrombosis 1653 coagulation and fibrinolysis is vital, as imbalance would lead to abnormal bleeding or increased risk of thrombosis . Thrombosis is pathological clot formation within the blood vessels in the absence of injury. In fact,
thrombosis 1786 pathological clot formation within the blood vessels in the absence of injury. In fact, the recognition of thrombosis has shaped treatment and prevention of vascular events such as acute coronary syndrome (ACS), which
thrombosis 1929 prevention of vascular events such as acute coronary syndrome (ACS), which is typically caused by arterial thrombosis following the rupture of vulnerable atheroma within the arterial wall [[1],[2],[3]].1.2. Atherosclerosis
thrombosis 2867 considered very vulnerable to rupture and are most causally associated with the occurrence of coronary thrombosis [[6]].1.3. Platelet Aggregation and Thrombus FormationFollowing plaque rupture, the exposure of tissue
thrombosis 3928 Endogenous or spontaneous fibrinolysis is the physiological counter-measure against lasting arterial thrombosis . It is divided into two key steps: (1) activation of plasminogen to serine proteinase plasmin by tissue
thrombosis 12696 employs a low-flow, static-type situation that more closely resembles venous, rather than arterial thrombosis .The Global Thrombosis Test (GTT, Thromboquest Ltd., London, UK) is a relatively new automated, point-of-care
thrombosis 12871 is a relatively new automated, point-of-care test that simultaneously assesses platelet reactivity, thrombosis , and fibrinolytic activity, from a native whole blood sample [[50]]. Blood passing through a plastic
thrombosis 13402 to do so is expressed as the lysis time (LT). The GTT provides a more comprehensive test to evaluate thrombosis and lysis under physiological conditions that closely resemble arterial thrombosis models. The evaluation
thrombosis 13485 test to evaluate thrombosis and lysis under physiological conditions that closely resemble arterial thrombosis models. The evaluation of GTT results in association with clinical outcomes has shown promise in various
thrombosis 13989 place to modify risk factors for patients at a population level. With the appreciation of the role that thrombosis and fibrinolysis plays in CVD [[54]], could we equate the measurement of fibrinolysis into defining
thrombosis 20882 of hyperfibrinolysis is well described in the literature, with regards of hypofibrinolysis (namely thrombosis risk assessment), it has had less success [[96]]. High platelet-fibrin clot strength (MA) has been linked
thrombosis 23169 and hypercholesterolemia are the targets for primary prevention drugs.Current treatment for arterial thrombosis relies on antiplatelet agents, such as aspirin, and P2Y12 inhibitors, such as clopidogrel or ticagrelor,
thrombosis 23378 ticagrelor, to help alleviate the pro-thrombotic environment. However, use of such medications to reduce thrombosis in allcomers puts many patients at unnecessary risk of bleeding [[106],[107]].Although the use of fibrinolytic
thrombosis 28536 unstable anginaOnly clot strength (MA) has been shown to help predict outcome.Not relevant to arterial thrombosis . Established method in hyperfibrinolytic status, i.e., bleeding. Limited data on hypofibrinolysis.No
vascular disease 1276 platelet thrombus formation, methods of measurement of fibrinolytic activity, its role in predicting cardio vascular disease s and clinical outcomes and future directions.1. Background1.1. HaemostasisHaemostasis is a complex sequence
vascular disease 13753 of future adverse cardiovascular event [[51],[52]].3.4. Measuring Lysis and Its Clinical ImpactCardio vascular disease (CVD) is the leading cause of death globally, accounting for 32% of deaths [[53]]. There are many interventions
vascular disease 22628 applications are summarised in Table 2.4. Current Situation, Limitations and Future DirectionsCardio vascular disease remains the leading cause of mortality and morbidity in the world despite many prevention and treatment
vascular disease 22806 world despite many prevention and treatment strategies. Currently in the UK, the screening for cardio vascular disease is done thorough risk scores (such as QRisk2) [[56]] to allow primary care practitioners to start primary
vascular disease 26246 cardiovascular research and provides an alternative viewpoint to the approach of treatment of cardio vascular disease . A number of different ways of assessing the capacity of the fibrinolytic pathways are available, which
vascular disease 27975 radiation.Factorial AssaysVarying reports of correlation between different assays and development of cardio vascular disease TAFI and PAI 1 have been found to correlate with clinical outcomes.Fluctuates over time and in response

You must be authorized to submit a review.